Coronavirus: Oxford vaccine ‘may be rolled out within weeks’ - but UK faces jab shortages
Mass production difficulties will limit early supplies
Two Covid-19 vaccines are on the verge of being certified as safe and effective - but production delays mean the first batches may reach no more than a fraction of the UK population.
A homegrown vaccine, developed by Oxford University and manufactured by AstraZeneca, has the “possibility of being ready before the end of the year”, according to Kate Bingham, the chair of the government’s vaccine task force.
She told MPs yesterday that the first three batches of the drug, now in production, “should get us up to about four million doses by the end of the year”. But as The Telegraph points out, the government pledged in May that “30 million vaccines would be ready by September to allow for immediate mass deployment if trials were successful”.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The delay is down to the technical challenge of splicing an immunity-generating protein from the coronavirus with a harmless chimpanzee virus that will carry it into human cells.
“It’s not through lack of care and attention or availability of equipment or anything like that,” Bingham said. “It’s just that this normally takes a very long time.”
Another potential vaccine, developed in Germany by Pfizer and BioNTech, is simpler to manufacture but “contains a type of genetic material known as mRNA that must be stored at minus 70C”, The Times reports. That makes it difficult and expensive to distribute.
The UK has signed deals to buy 350 million doses of a total of six vaccines, all of which are undergoing trials. Once the results are published, the government’s health authorities will decide whether to approve their widespread use.
“The US regulator, the Food and Drug Administration, has said it wanted at least 50% efficacy to approve a vaccine,” The Guardian reports. “But if one was found to prevent 40% of cases, [UK] policymakers would have to consider whether it would be of help to the NHS.”
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Holden Frith is The Week’s digital director. He also makes regular appearances on “The Week Unwrapped”, speaking about subjects as diverse as vaccine development and bionic bomb-sniffing locusts. He joined The Week in 2013, spending five years editing the magazine’s website. Before that, he was deputy digital editor at The Sunday Times. He has also been TheTimes.co.uk’s technology editor and the launch editor of Wired magazine’s UK website. Holden has worked in journalism for nearly two decades, having started his professional career while completing an English literature degree at Cambridge University. He followed that with a master’s degree in journalism from Northwestern University in Chicago. A keen photographer, he also writes travel features whenever he gets the chance.
-
Today's political cartoons - March 16, 2024
Cartoons Saturday's cartoons - pointed commentary, Haiti in trouble, and more
By The Week US Published
-
5 hilarious cartoons about the RNC's MAGA takeover
Cartoons Artists take on RNC funding, Lara Trump, and more
By The Week US Published
-
Trump's presidential run: a bad bet for Republicans?
Talking Point The GOP is taking a 'big gamble' on former president's 2024 White House bid
By The Week UK Published
-
Will new Welsh leader change UK relations?
Today's Big Question Vaughan Gething or Jeremy Miles will have to decide how closely to follow Keir Starmer when they become first minister
By Sorcha Bradley, The Week UK Published
-
It's the economy, Sunak: has 'Rishession' halted Tory fightback?
Today's Big Question PM's pledge to deliver economic growth is 'in tatters' as stagnation and falling living standards threaten Tory election wipeout
By Harriet Marsden, The Week UK Published
-
Nicola Sturgeon and the Covid Inquiry: another blow to her reputation?
Talking Point Scotland's ex-leader provokes outrage with testimony to Covid Inquiry about deleted WhatsApp messages from pandemic
By The Week UK Published
-
Nicola Sturgeon admits errors in handling of pandemic
Speed Read Scotland's former first minister accused of 'crocodile tears' at Covid inquiry
By Arion McNicoll, The Week UK Published
-
Why your local council may be going bust
The Explainer Across England, local councils are suffering from grave financial problems
By The Week UK Published
-
Rishi Sunak and the right-wing press: heading for divorce?
Talking Point The Telegraph launches 'assault' on PM just as many Tory MPs are contemplating losing their seats
By Keumars Afifi-Sabet, The Week UK Published
-
'Making Russia pay for its aggression with its own assets has undeniable moral and practical appeal'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
'Expat voters could fuel backlash against government at next election'
Instant Opinion Opinion, comment and editorials of the day
By The Week UK Published